Clinical trials: Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
This study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS).
- Trial name
- KATHAROS (NCT06444113)
- Testing
- Ofatunumab
- Where
- 15 sites in United States, Germany and 3 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
NOGO-A in Multiple Sclerosis FTIH
The drug being tested in this study is GSK1223249. The drug works by inhibiting a protein that prevents nerve growth. The trial is expected to involve approximately 36 patients.
- Trial name
- NCT01424423
- Testing
- GSK1223249
- Where
- Australia
- Volunteers
- 3 people
- Sponsor
- GlaxoSmithKline
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.
It is thought that treating multiple sclerosis with Novantrone for a short period of time prior to treatment with Copaxone may enhance the onset effect of Copaxone.
- Trial name
- NCT00203073
- Testing
- glatiramer acetate 20 mg, glatiramer acetate 20 mg, with mitoxantrone
- Volunteers
- 40 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Myasthenia Gravis
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or…
- Trial name
- NCT06220201
- Testing
- CC-97540, Fludarabine, Cyclophosphamide
- Where
- 34 sites in United States, Belgium and 4 more
- Volunteers
- 120 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Sclerosis
Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada
Primary Objective: To collect blood samples in a new cohort of Relapsing Forms of Multiple Sclerosis (RMS) participants who had developed immune thrombocytopenic purpura (ITP) after LEMTRADA treatment, for future Deoxyribonucleic…
- Trial name
- LEMTRADA-ITP (NCT03784898)
- Testing
- Blood draw for future biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Genzyme, a Sanofi Company
Relapsing Multiple Sclerosis (RMS)
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/IV…
- Trial name
- ULTIMATE II (NCT03277248)
- Testing
- Ublituximab, Teriflunomide
- Where
- 13 sites in United States
- Volunteers
- 545 people
- Sponsor
- TG Therapeutics, Inc.
Multiple Sclerosis
Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina
This observational study is being conducted to evaluate the usefulness of the MSFC and its relationship with EDSS scores in subjects with MS in Argentina.
- Trial name
- NCT01080014
- Where
- Argentina
- Volunteers
- 252 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Safety Study of GNbAC1 in Multiple Sclerosis Patients
The purpose of this study is to assess the safety and tolerability of single ascending doses, as well as of repeated administrations of GNbAC1 in MS patients.
- Trial name
- NCT01639300
- Testing
- GNbAC1
- Where
- 2 sites in Switzerland
- Volunteers
- 10 people
- Sponsor
- GeNeuro Innovation SAS
Multiple Sclerosis
Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
This research study is being conducted in the U.S. and Europe to evaluate the safety and efficacy of daclizumab for the treatment of multiple sclerosis (MS).
- Trial name
- NCT00109161
- Testing
- Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
- Where
- 36 sites in United States, Canada
- Volunteers
- 270 people
- Sponsor
- PDL BioPharma, Inc.
Multiple Sclerosis
Natalizumab High Titer Immunogenicity and Safety
The primary objective of the study was to evaluate the immunogenicity of natalizumab (Tysabri®) produced by a modified manufacturing process (natalizumab high titer; BG00002-E) administered intravenously (IV) to participants with…
- Trial name
- NCT00516893
- Testing
- BG00002-E (natalizumab high titer)
- Where
- 13 sites in United States
- Volunteers
- 113 people
- Sponsor
- Biogen
Relapsing Forms of Multiple Sclerosis
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
The primary objectives of this study are to determine the safety and tolerability of DRF administered for up to 24 weeks in adult East Asian participants with RMS (Part 1) and to determine the safety and tolerability of DRF…
- Trial name
- NCT05083923
- Testing
- Diroximel fumarate
- Where
- 52 sites in China, Japan
- Volunteers
- 136 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
An Extension of the TG1101-RMS201 Trial
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis
- Trial name
- NCT03381170
- Testing
- Ublituximab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- TG Therapeutics, Inc.
Relapsing Forms of MS
Exploring Diroximel Fumarate Real-world Experience in Canada and Israel
The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice.
- Trial name
- EXPER-CA/IL (NCT04948606)
- Testing
- Diroximel Fumarate
- Where
- 6 sites in Israel
- Volunteers
- 64 people
- Sponsor
- Biogen
Relapsing Multiple Sclerosis
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
The primary objective of this study is to demonstrate that the incidence of progressive multifocal Leukoencephalopathy (PML) in natalizumab-treated participants who do not have detectable antibodies to John Cunningham virus (JCV)…
- Trial name
- STRATIFY-2 (NCT01070836)
- Testing
- natalizumab
- Where
- 478 sites in United States, Puerto Rico
- Volunteers
- 35,895 people
- Sponsor
- Biogen
Multiple Sclerosis
Tecfidera Lymphocyte Chart Review
The primary objective of the study is to retrospectively investigate changes in lymphocyte counts and lymphocyte subtypes, with a focus on CD4+ and CD8+ T cells, in participants on Tecfidera therapy for at least 6 months.
- Trial name
- REALIZE (NCT02519413)
- Testing
- dimethyl fumarate
- Where
- 10 sites in United States
- Volunteers
- 483 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.
This study will investigate how 3 new types of drug formulations are absorbed by the body. This study is termed 'open-label', which means volunteers will be aware of which treatment they are receiving.
- Trial name
- NCT01424462
- Testing
- A, B, C
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis
The primary objective of the study is to compare the immunogenicity of the new fetal bovine serum (FBS)-free/human serum albumin (HSA)-free Rebif® formulation (RNF) to historical data.
- Trial name
- RNF (NCT00110396)
- Testing
- Interferon-beta-1a FBS-free/HSA-free
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Relapsing-Remitting
Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis
A Web based real world observational study in Relapsing-Remitting Multiple Sclerosis (RRMS) population capturing outcomes reported by patients and by the physicians during 12 months after initiating or resuming Betaseron.
- Trial name
- ROBUST (NCT01158183)
- Testing
- BAY86-5046_Interferon-beta-1b
- Where
- 27 sites in United States
- Volunteers
- 226 people
- Sponsor
- Bayer
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis
It is thought that treating Multiple Sclerosis with Novantrone for a short period of time prior to treatment with Copaxone may enhance the onset effect of Copaxone.
- Trial name
- NCT00203086
- Volunteers
- 30 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis
This is a study to count the number of white blood cells in the cerebrospinal fluid and blood at the beginning and end of treatment with firategrast and at 4 and 12 weeks after stopping firategrast.
- Trial name
- NCT00469378
- Testing
- firategrast
- Where
- 10 sites in Belgium, Czechia and 3 more
- Volunteers
- 46 people
- Sponsor
- GlaxoSmithKline